i-STAT ACT Readings Support a Lower Heparin Target in Neurointerventional Radiology
A decade of bedside anticoagulation practice can hinge on a few seconds of clotting time. In this academic medical center study, activated clotting time monitoring in neurointerventional radiology shifted toward a lower target range after i-STAT produced more reproducible readings than Hemochron and aligned well with laboratory anti-Xa results inside the therapeutic window.
The practical consequence was immediate: the historical Hemochron target of 250 to 300 seconds moved down to 200 to 250 seconds for i-STAT devices. The change was not cosmetic. It reflected a direct comparison of two point-of-care systems against a laboratory marker of heparin effect in a setting where even small anticoagulation errors can carry neurologic consequences.
Duplicate Testing Exposed Meaningful Device-to-Device Variation
Investigators compared ACT performance using two Hemochron and two i-STAT devices across 53 samples drawn from 15 unique multidose heparin administrations during NIR procedures. For perspective, the same group also examined 110 samples from cardiovascular procedures, allowing a broader look at instrument behavior beyond the neurointerventional suite. Every ACT measurement was performed in duplicate, and paired samples were obtained within 1 minute of each other, a design that reduced the chance that changing heparin levels alone explained the differences.
Interinstrument variability ran higher with Hemochron than with i-STAT. In a procedural field where operators dose heparin repeatedly to prevent thrombus formation on wires, catheters, and devices, reproducibility matters as much as the absolute value. A monitoring tool that drifts between machines can widen the gap between intended anticoagulation and actual clinical exposure. i-STAT’s tighter performance therefore carries bedside weight, not just laboratory appeal.
Lower ACT values also emerged with i-STAT compared with Hemochron. In response, the older 250 to 300 second Hemochron range was recalibrated to 200 to 250 seconds for i-STAT devices, indicating that identical numeric thresholds could have overstated heparin effect if applied without adjustment.
Anti-Xa Correlation Held in Range, Then Split Above It
The laboratory anti-Xa assay gave the comparison clinical anchor. For 12 of the 15 NIR procedures, anti-Xa was measured at the beginning of the case and again at the end of all procedural dosing, creating a before-and-after view of heparin exposure. Inside the therapeutic anti-Xa range, ACT values from both instruments showed a linear correlation. In that zone, rising clotting time tracked heparin effect in a predictable way.
Outside the therapeutic window, the instruments separated. At supratherapeutic anti-Xa levels, Hemochron ACT remained more linearly correlated, while i-STAT displayed a plateau effect. Biologically, that pattern makes sense: once coagulation enzymes are suppressed enough, some point-of-care systems lose sensitivity and stop stretching proportionally with added heparin. In a neurointerventional case, that ceiling can matter if operators assume a longer ACT always means meaningfully deeper anticoagulation. The plateau suggests that i-STAT is dependable within the target range but less informative once heparin effect becomes excessive.
No Severe Postprocedural Neurologic Bleeding Was Detected
The most clinically reassuring signal was the absence of severe postprocedural neurologic bleeding. Patient charts were reviewed anonymously for evidence of that outcome, and none was identified. For a specialty that works inside or near cerebral vessels, the margin between thrombosis and hemorrhage is narrow, and the combination of anti-Xa confirmation plus no severe bleeding supports the lowered ACT window as a defensible operational target.
This does not mean the number alone guarantees safety. Rather, it suggests that a 200 to 250 second i-STAT target can preserve procedural anticoagulation without obvious excess hemorrhagic harm in this cohort. The finding also argues against reflexively carrying over ACT thresholds from one platform to another. Device calibration, signal behavior at high heparin levels, and local procedural technique all influence how a clotting target should be interpreted at the bedside.
Why the Lower Target Matters at the Bedside
Neurointerventional procedures depend on a narrow anticoagulation corridor. Too little heparin raises the risk of catheter-associated thrombosis and ischemic embolic events. Too much increases the chance of intracranial or access-site bleeding, a complication with immediate neurologic consequences. ACT is attractive because it is rapid and available during the case, but it is still a surrogate, and this study shows that surrogate performance depends on the platform in use.
The findings also reinforce a broader point about procedural heparin management: point-of-care numbers should be interpreted in the context of the instrument generating them. Hemochron and i-STAT did not deliver interchangeable values, and the safer clinical path was to retune the target range rather than force one system to mimic the other. That approach preserves the bedside utility of ACT while preserving alignment with anti-Xa behavior and observed outcomes.
For academic centers and interventional teams using i-STAT in NIR, the operational message is concrete. A lower target range of 200 to 250 seconds appears to deliver reproducible ACT monitoring with laboratory correlation in the therapeutic anti-Xa range and without observed severe neurologic bleeding in this series. The unresolved question is not whether ACT remains useful, but how much local validation should precede changes in heparin targets when a different analyzer enters the room.